|
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer Clinical research trials and Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer. Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer clinical trial. Subjects often receive the most expert healthcare possible for their Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer  Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
For Condition: stage 3 prostate cancer,stage 2 prostate cancer,adenocarcinoma of the prostate
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Dana-Farber/Harvard Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.
Details: OBJECTIVES: I. Determine the pathologic complete response rate to docetaxel in patients with high risk stage II or III prostate cancer. II. Determine the toxicity of this treatment in these patients. III. Correlate clinical measures of response (e.g., symptoms, physical exam, serum PSA, and endorectal MRI) with pathologic response to this treatment in these patients. PROTOCOL OUTLINE: Patients receive docetaxel IV over 30 minutes weekly for 4 weeks. Treatment continues for 2-6 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 19-45 patients will be accrued for this study over 18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/85 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed adenocarcinoma of the prostate - Potential candidate for radical prostatectomy - Any of the following: Clinical stage T3 patients; Serum PSA at least 20 ng/mL; Gleason score 8-10; Clinical T2 disease and either of the following: MRI evidence of seminal vesicle involvement; Gleason 4+3 cancer with either 5 or 6 biopsies positive --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy for prostate cancer - Endocrine therapy: No prior hormonal therapy for prostate cancer - Radiotherapy: No prior radiotherapy for prostate cancer - Surgery: See Disease Characteristics; No prior surgery for prostate cancer --Patient Characteristics-- - Age: 18 to 85 - Performance status: CALGB 0-1 - Life expectancy: Not specified - Hematopoietic: WBC greater than 3,000/mm3; Hematocrit greater than 30%; Platelet count greater than 100,000/mm3 - Hepatic: SGOT and bilirubin normal - Renal: Not specified - Other: No active infection; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WilliamOh, Study Chair, Dana-Farber/Harvard Cancer Center
Brigham and Women's Hospital
Boston, Massachusetts, 02115
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
United States
Additional Information:
Study ID Numbers: CDR0000067764; DFCI-99193,NCI-G00-1757
Study Start Date: December 1999
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005096
Other Adenocarcinoma Of The Prostate Studies:
1. CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who are Undergoing Radiation Therapy
2. Neoadjuvant Thalidomide in Treating Patients With Locally Advanced Prostate Cancer Who Are Undergoing Radical Prostatectomy
3. Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer
4. Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
5. Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Related Studies:
Other adenocarcinoma of the prostate Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
|
|
|
|
|
|
|
|
